Understanding Alzheimer's Disease to Improve Biomarkers and Treatments

Leveraging Heterogeneity in Autosomal Dominant AD to Elucidate Pathophysiology and Improve AD Biomarkers

NIH-funded research Brigham and Women's Hospital · NIH-10539956

This study is looking at how certain genetic changes can affect the way the brain produces a protein linked to Alzheimer's disease, helping us understand why some people have symptoms sooner or more intensely, with the hope of finding new ways to treat the condition.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionBrigham and Women's Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10539956 on NIH RePORTER

What this research studies

This research investigates the mechanisms behind Alzheimer's disease (AD) by focusing on genetic variations that affect the production of amyloid-beta proteins, which are crucial in the disease's progression. By studying different mutations in the Presenilin-1 gene, the research aims to uncover why some individuals experience symptoms earlier or more severely than others. The approach includes laboratory experiments using cell models to analyze how these mutations influence the function of a key protein complex involved in amyloid production. The ultimate goal is to identify new biomarkers and therapeutic targets that could lead to better treatments for Alzheimer's disease.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals with a family history of autosomal dominant Alzheimer's disease or those diagnosed with early-onset Alzheimer's.

Not a fit: Patients with sporadic Alzheimer's disease without a known genetic mutation may not benefit directly from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic tools and more effective treatments for Alzheimer's disease.

How similar studies have performed: Previous research has shown promise in understanding genetic factors in Alzheimer's disease, indicating that this approach could yield valuable insights.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer's DiseaseAlzheimer diseaseAlzheimer syndromeAlzheimer's disease dementiaAlzheimers disease
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.